Compare Nvidia Corp (NVDA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Novo Nordisk A/S — how do they compare? Nvidia Corp trades at $221.24 (market cap $5.27T), while Novo Nordisk A/S trades at $47.65 (market cap $207.31B). The key difference: Nvidia Corp is far larger — about 25.4× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.76%). Which is the better fit depends on your goals.
| NVDA | NVO | |
|---|---|---|
Market Cap | $5.27T | $207.31B |
Sector | Technology | Health |
52-Week High | $235.75 | $63.98 |
52-Week Low | $165.17 | $35.29 |
Enterprise Value | $5.20T | $222.02B |
Dividend Yield | 0.46% | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $223.96, up 2.27% on the day, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $1.87 surpassing the $1.76 expectation. Revenue surged to $130.50 billion in 2025, driving a net income margin of 62.97%. Analyst consensus is strongly bullish with a $325.86 price target, though RSI levels indicate potential overbought conditions near-term.
Outlook remains positive due to AI chip dominance and accelerating revenue growth, but risks include heightened valuations, competition, and market volatility. The stock offers significant upside to analyst targets, supported by robust cash flow and institutional backing, though investors should monitor execution against high expectations.
Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.
Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
